Literature DB >> 17239482

Immunological techniques in viral hepatitis.

Barbara Rehermann1, Nikolai V Naoumov.   

Abstract

The need to quantitate and monitor immune responses of large patient cohorts with standardized techniques is increasing due to the growing range of treatment options for hepatitis B and hepatitis C, the development of combination therapies, and candidate experimental vaccines for HCV. In addition, advances in immunological techniques have provided new tools for detailed phenotypic and functional analysis of cellular immune responses. At present, there is substantial variation in laboratory protocols, reagents, controls and analysis and presentation of results. Standardization of immunological assays would therefore allow better comparison of results amongst individual laboratories and patient cohorts. The EASL-sponsored and AASLD-endorsed Monothematic Conference on Clinical Immunology in Viral Hepatitis was held at the University College London, United Kingdom, Oct 7-8, 2006 to bring together investigators with research experience in clinical immunology of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections for in-depth discussion, critical evaluation and standardization of immunological assays. This report summarizes the information presented and discussed at the conference, but is not intended to represent a consensus statement. Our aim is to highlight topics and issues that were supported by general agreement and those that were controversial, as well as to provide suggestions for future work.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17239482     DOI: 10.1016/j.jhep.2007.01.002

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  13 in total

1.  Activated natural killer cells accelerate liver damage in patients with chronic hepatitis B virus infection.

Authors:  Q Zheng; Y Y Zhu; J Chen; Y B Ye; J Y Li; Y R Liu; M L Hu; Y C Zheng; J J Jiang
Journal:  Clin Exp Immunol       Date:  2015-04-12       Impact factor: 4.330

2.  Hypercytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients.

Authors:  Zheng Zhang; Shuye Zhang; Zhengsheng Zou; Jianfei Shi; Juanjuan Zhao; Rong Fan; Enqiang Qin; Baosen Li; Zhiwei Li; Xiangsheng Xu; Junliang Fu; Jiyuan Zhang; Bin Gao; Zhigang Tian; Fu-Sheng Wang
Journal:  Hepatology       Date:  2010-10-26       Impact factor: 17.425

3.  The kinetics of hepatitis C virus-specific CD8 T-cell responses in the blood mirror those in the liver in acute hepatitis C virus infection.

Authors:  Eui-Cheol Shin; Stefania Capone; Riccardo Cortese; Stefano Colloca; Alfredo Nicosia; Antonella Folgori; Barbara Rehermann
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

4.  Determination of HCV-specific T-cell activity.

Authors:  Joo Chun Yoon; Barbara Rehermann
Journal:  Methods Mol Biol       Date:  2009

5.  Immune and viral profile from tolerance to hepatitis B surface antigen clearance: a longitudinal study of vertically hepatitis B virus-infected children on combined therapy.

Authors:  Ivana Carey; Lorenzo D'Antiga; Sanjay Bansal; Maria Serena Longhi; Yun Ma; Irene Rebollo Mesa; Giorgina Mieli-Vergani; Diego Vergani
Journal:  J Virol       Date:  2010-12-08       Impact factor: 5.103

6.  Cellular immune responses in patients with hepatitis B surface antigen seroclearance induced by antiviral therapy.

Authors:  Minfeng Liang; Shiwu Ma; Xiaoxiong Hu; Bin Zhou; Junchang Zhang; Jinjun Chen; Zhanhui Wang; Jian Sun; Xiaolin Zhu; William Abbott; Jinlin Hou
Journal:  Virol J       Date:  2011-02-14       Impact factor: 4.099

7.  Rapid early innate control of hepatitis C virus during IFN-α treatment compromises adaptive CD4+ T-cell immunity.

Authors:  Tom Pembroke; Ian Rees; Kathleen Gallagher; Emma Jones; Paul Mizen; Timur Navruzov; Andrew Freedman; Ceri Fielding; Ian R Humphreys; Eddie C Y Wang; Awen M Gallimore; Andrew Godkin
Journal:  Eur J Immunol       Date:  2012-08-06       Impact factor: 5.532

8.  Changes to the natural killer cell repertoire after therapeutic hepatitis B DNA vaccination.

Authors:  Daniel Scott-Algara; Maryline Mancini-Bourgine; Hélène Fontaine; Stanislas Pol; Marie-Louise Michel
Journal:  PLoS One       Date:  2010-01-18       Impact factor: 3.240

9.  The intracellular detection of MIP-1beta enhances the capacity to detect IFN-gamma mediated HIV-1-specific CD8 T-cell responses in a flow cytometric setting providing a sensitive alternative to the ELISPOT.

Authors:  Sarah Kutscher; Claudia J Dembek; Simone Allgayer; Silvia Heltai; Birgit Stadlbauer; Priscilla Biswas; Silvia Nozza; Giuseppe Tambussi; Johannes R Bogner; Hans J Stellbrink; Frank D Goebel; Paolo Lusso; Marco Tinelli; Guido Poli; Volker Erfle; Heike Pohla; Mauro Malnati; Antonio Cosma
Journal:  AIDS Res Ther       Date:  2008-10-06       Impact factor: 2.250

10.  Decreased peripheral natural killer cells activity in the immune activated stage of chronic hepatitis B.

Authors:  Yuan Li; Jiu-Jun Wang; Shan Gao; Qian Liu; Jia Bai; Xue-Qi Zhao; You-Hua Hao; Hong-Hui Ding; Fan Zhu; Dong-Liang Yang; Xi-Ping Zhao
Journal:  PLoS One       Date:  2014-02-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.